Thyroid-stimulation hormone-receptor antibodies as a predictor of thyrosuppressive drug therapy outcome in Graves' disease patients.

INTRODUCTION Graves' disease is autoimmune hyperthyroidism caused by pathological stimulation of thyroid-stimulation hormone-receptor antibodies. The decision on changing the therapy can be made on time by determining the prognostic factors of thyrosuppressive drug therapy outcome. The aim of the study was to determine the significance of thyroid-stimulation hormone-receptor antibodies level on the prediction of therapy outcome. MATERIAL AND METHODS The study was prospective and involved 106 drug-treated patients with newly diagnosed Graves' disease. Thyroid-stimulation hormone-receptor antibodies level was measured at the beginning of therapy, during therapy and 12 months after it had been introduced. RESULTS No statistically significant difference in the level of thyroid-stimulation hormone-receptor antibodies was found at the beginning of disease and 12 months after the introduction of thyrosuppressive drug therapy among the patients who had been in remission and those who had not. Regardless of the outcome, thyroid-stimulation hormone-receptor antibodies level significantly decreased in all patients 12 months after the therapy had been introduced. CONCLUSION The level of thyroid-stimulation hormone-receptor antibodies at the beginning of disease and 12 months after the introduction of therapy cannot predict the outcome of thyrosuppressive drug therapy.

[1]  G. Omrani,et al.  PROGNOSTIC FACTORS IN THE RELAPSE OF GRAVES DISEASE FOLLOWING TREATMENT WITH ANTITHYROID DRUGS , 2015 .

[2]  L. Degroot.  Graves’ Disease and the Manifestations of Thyrotoxicosis , 2015 .

[3]  E. J. Lee,et al.  Correlation between TSH Receptor Antibody Assays and Clinical Manifestations of Graves' Orbitopathy , 2013, Yonsei medical journal.

[4]  G. Krause,et al.  G-protein-coupled Receptors: from Structural Insights to Functional Mechanisms Molecular Sampling of the Allosteric Binding Pocket of the Tsh Receptor Provides Discriminative Pharmacophores for Antagonist and Agonists , 2022 .

[5]  Wei-fang Li,et al.  Polymorphisms in the vitamin D receptor gene and risk of autoimmune thyroid diseases: a meta-analysis , 2013, Endocrine.

[6]  L. Premawardhana,et al.  The Role of Thyrotrophin Receptor Antibody Assays in Graves' Disease , 2012, Journal of thyroid research.

[7]  R. Bahn,et al.  Autoimmunity and Graves’ Disease , 2012, Clinical pharmacology and therapeutics.

[8]  Y. Okamoto,et al.  Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. , 2011, Endocrine journal.

[9]  K. Mann,et al.  Clinical value of TSH receptor antibodies measurement in patients with Graves' orbitopathy. , 2010, Pediatric endocrinology reviews : PER.

[10]  A. Nikolic,et al.  [TRAb determination in newly detected patients with hyperthyroidism and their prognostic importance]. , 2009, Medicinski pregled.

[11]  A. Aleksić,et al.  TSH receptor antibodies for confirming the diagnosis and prediction of remission duration, in newly diagnosed Graves' disease patients. , 2009, Hellenic journal of nuclear medicine.

[12]  P. Czernichow,et al.  Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. , 2008, The Journal of clinical endocrinology and metabolism.

[13]  C. Coeli,et al.  Use of Clinical and Laboratory Data for Prediction of Gravesʼ Disease 1-Year Remission After 12 Months of Treatment With Antithyroid Drugs , 2008 .

[14]  M. Castellano,et al.  Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study. , 2007, Endocrine journal.

[15]  T. Bednarczuk,et al.  Predicting a relapse of Graves' hyperthyroidism in adults during the early phase of treatment with anti-thyroid drugs. , 2006, Endokrynologia Polska.

[16]  P. Diem,et al.  [Long-term follow up after antithyroid drug treatment in Graves' disease]. , 2006, Praxis.

[17]  U. Roggenbuck,et al.  Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease. , 2005, Thyroid : official journal of the American Thyroid Association.

[18]  S. Fountoulakis,et al.  On the pathogenesis of autoimmune thyroid disease: a unifying hypothesis , 2004, Clinical endocrinology.

[19]  S. Skeie,et al.  Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. , 2002, European journal of endocrinology.

[20]  M. González-Ortiz,et al.  Remission of Graves' hyperthyroidism treated with methimazole. , 2002, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[21]  D. Glinoer,et al.  Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. , 2001, European journal of endocrinology.

[22]  N. Paunković,et al.  MEDICAL CENTRE ZAJECAR, SERVICE OF NUCLEAR MEDICINE VALUES OF TSH RECEPTOR AUTOANTIBODIES IN PATIENTS WITH TREATED GRAVES' DISEASE , 1991 .

[23]  B. Nygaard,et al.  Use of the 2 nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves ’ disease , 2022 .